Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2009 (2009), Article ID 139590, 5 pages
http://dx.doi.org/10.1155/2009/139590
Clinical Study

Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer

1Department of General, Visceral and Tumor Surgery, University of Cologne, 50931 Cologne, Germany
2Internal Medicine Clinic I, Carl Gustav Carus University Hospital, Dresden, Germany
3Department of Visceral and Transplant Surgery, University Clinic Zürich, Zurich, Switzerland
4Faculty of Biochemistry and Molecular Biology, University of Southern California, Los Angeles, CA 90089, USA

Received 21 May 2009; Accepted 4 September 2009

Academic Editor: Frederick E. Domann

Copyright © 2009 Peter P. Grimminger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. S. Hecht, “Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention,” Lancet Oncology, vol. 3, no. 8, pp. 461–469, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Google Scholar · View at Scopus
  3. American Cancer Society, “Cancer Facts & Figures 2008,” American Cancer Society, Atlanta, Ga, USA, 2008.
  4. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Siemes, L. E. Visser, J. W. W. Coebergh, A. Hofman, A. G. Uitterlinden, and B. H. C. Stricker, “Protective effect of NSAIDs on cancer and influence of COX-2 C-765G genotype,” Current Cancer Drug Targets, vol. 8, no. 8, pp. 753–764, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. E. J. Jacobs, M. J. Thun, E. B. Bain, C. Rodriguez, S. J. Henley, and E. E. Calle, “A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence,” Journal of the National Cancer Institute, vol. 99, no. 8, pp. 608–615, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Thun, M. M. Namboodiri, and C. W. Heath Jr., “Aspirin use and reduced risk of fatal colon cancer,” The New England Journal of Medicine, vol. 325, no. 23, pp. 1593–1596, 1991. View at Google Scholar · View at Scopus
  8. R. E. Harris, J. Beebe-Donk, H. Doss, and D. Burr Doss, “Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review),” Oncology Reports, vol. 13, no. 4, pp. 559–583, 2005. View at Google Scholar · View at Scopus
  9. J. R. Vane, Y. S. Bakhle, and R. M. Botting, “Cyclooxygenases 1 and 2,” Annual Review of Pharmacology and Toxicology, vol. 38, pp. 97–120, 1998. View at Google Scholar · View at Scopus
  10. J. R. Vane and R. M. Botting, “Mechanism of action of aspirin-like drugs,” Seminars in Arthritis and Rheumatism, vol. 26, no. 6, supplement 2, pp. 2–10, 1997. View at Google Scholar · View at Scopus
  11. A. Koki, N. K. Khan, B. M. Woerner et al., “Cyclooxygenase-2 in human pathological disease,” Advances in Experimental Medicine and Biology, vol. 507, pp. 177–184, 2002. View at Google Scholar · View at Scopus
  12. C. E. Eberhart, R. J. Coffey, A. Radhika, F. M. Giardiello, S. Ferrenbach, and R. N. Dubois, “Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas,” Gastroenterology, vol. 107, no. 4, pp. 1183–1188, 1994. View at Google Scholar · View at Scopus
  13. H. Sano, Y. Kawahito, R. L. Wilder et al., “Expression of cyclooxygenase-1 and -2 in human colorectal cancer,” Cancer Research, vol. 55, no. 17, pp. 3785–3789, 1995. View at Google Scholar · View at Scopus
  14. O. N. Tucker, A. J. Dannenberg, E. K. Yang et al., “Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer,” Cancer Research, vol. 59, no. 5, pp. 987–990, 1999. View at Google Scholar · View at Scopus
  15. D. Hwang, D. Scollard, J. Byrne, and E. Levine, “Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer,” Journal of the National Cancer Institute, vol. 90, no. 6, pp. 455–460, 1998. View at Google Scholar · View at Scopus
  16. K. C. Zimmermann, M. Sarbia, A.-A. Weber, F. Borchard, H. E. Gabbert, and K. Schror, “Cyclooxygenase-2 expression in human esophageal carcinoma,” Cancer Research, vol. 59, no. 1, pp. 198–204, 1999. View at Google Scholar · View at Scopus
  17. A. Ristimaki, N. Honkanen, H. Jankala, P. Sipponen, and M. Harkonen, “Expression of cyclooxygenase-2 in human gastric carcinoma,” Cancer Research, vol. 57, no. 7, pp. 1276–1280, 1997. View at Google Scholar · View at Scopus
  18. R. A. Soslow, A. J. Dannenberg, D. Rush et al., “COX-2 is expressed in human pulmonary, colonic, and mammary tumors,” Cancer, vol. 89, no. 12, pp. 2637–2645, 2000. View at Google Scholar
  19. H. Wolff, K. Saukkonen, S. Anttila, A. Karjalainen, H. Vainio, and A. Ristimaki, “Expression of cyclooxygenase-2 in human lung carcinoma,” Cancer Research, vol. 58, no. 22, pp. 4997–5001, 1998. View at Google Scholar · View at Scopus
  20. P. Uotila, E. Valve, P. Martikainen, M. Nevalainen, M. Nurmi, and P. Harkonen, “Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer,” Urological Research, vol. 29, no. 1, pp. 25–28, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Kulkarni, J. S. Rader, F. Zhang et al., “Cyclooxygenase-2 is overexpressed in human cervical cancer,” Clinical Cancer Research, vol. 7, no. 2, pp. 429–434, 2001. View at Google Scholar · View at Scopus
  22. T. Shirahama, “Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder,” Clinical Cancer Research, vol. 6, no. 6, pp. 2424–2430, 2000. View at Google Scholar · View at Scopus
  23. B. J. Tong, J. Tan, L. Tajeda et al., “Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta human endometrial adenocarcinoma,” Neoplasia, vol. 2, no. 6, pp. 483–490, 2000. View at Google Scholar · View at Scopus
  24. E. Goekkurt, S. Hoehn, C. Wolschke et al., “Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)—novel predictors for response and survival in gastric cancer patients,” British Journal of Cancer, vol. 94, no. 2, pp. 281–286, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Marcuello, A. Altes, E. del Rio, A. Cesar, A. Menoyo, and M. Baiget, “Single nucleotide polymorphism in the 5 tandem repeat sequences of Thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients,” International Journal of Cancer, vol. 112, no. 5, pp. 733–737, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. V. Cohen, V. Panet-Raymond, N. Sabbaghian, I. Morin, G. Batist, and R. Rozen, “Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy,” Clinical Cancer Research, vol. 9, no. 5, pp. 1611–1615, 2003. View at Google Scholar · View at Scopus
  27. J. Stoehlmacher, D. J. Park, W. Zhang et al., “A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer,” British Journal of Cancer, vol. 91, no. 2, pp. 344–354, 2004. View at Google Scholar · View at Scopus
  28. W. Zhou, S. Gurubhagavatula, G. Liu et al., “Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy,” Clinical Cancer Research, vol. 10, no. 15, pp. 4939–4943, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. J.-H. Pan, J.-X. Han, J.-M. Wu, L.-J. Sheng, H.-N. Huang, and Q.-Z. Yu, “MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer,” Respiration, vol. 75, no. 4, pp. 380–385, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Papafili, M. R. Hill, D. J. Brull et al., “Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 10, pp. 1631–1636, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Campa, S. Zienolddiny, V. Maggini, V. Skaug, A. Haugen, and F. Canzian, “Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer,” Carcinogenesis, vol. 25, no. 2, pp. 229–235, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. P. M. Schneider, H. W. Praeuer, O. Stoeltzing et al., “Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer,” British Journal of Cancer, vol. 83, no. 4, pp. 473–479, 2000. View at Google Scholar · View at Scopus
  33. C. F. Mountain, “Revisions in the international system for staging lung cancer,” Chest, vol. 111, no. 6, pp. 1710–1717, 1997. View at Google Scholar · View at Scopus
  34. R. Miller and D. Siegmund, “Maximally selected chi square statistics,” Biometrics, vol. 38, no. 4, pp. 1011–1016, 1982. View at Google Scholar · View at Scopus
  35. E. Kaplan and P. Meier, “Nonparametric estimation from incomplete observations,” The Journal of the American Medical Association, vol. 53, pp. 457–481, 1958. View at Google Scholar
  36. A. J. Dannenberg and K. Subbaramaiah, “Targeting cyclooxygenase-2 in human neoplasia: rationale and promise,” Cancer Cell, vol. 4, no. 6, pp. 431–436, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. D. S. Dandekar and B. L. Lokeshwar, “Inhibition of cyclooxygenase (COX)-2 expression by tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs,” Clinical Cancer Research, vol. 10, no. 23, pp. 8037–8047, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Kishi, S. Petersen, C. Petersen et al., “Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor,” Cancer Research, vol. 60, no. 5, pp. 1326–1331, 2000. View at Google Scholar · View at Scopus
  39. M. Oshima, J. E. Dinchuk, S. L. Kargman et al., “Suppression of intestinal polyposis in Apc(delta716) knockout mice by inhibition of cyclooxygenase 2 (COX-2),” Cell, vol. 87, no. 5, pp. 803–809, 1996. View at Publisher · View at Google Scholar · View at Scopus
  40. F. R. Khuri, H. Wu, J. J. Lee et al., “Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer,” Clinical Cancer Research, vol. 7, no. 4, pp. 861–867, 2001. View at Google Scholar · View at Scopus
  41. A. Yuan, C.-J. Yu, C.-T. Shun et al., “Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients,” International Journal of Cancer, vol. 115, no. 4, pp. 545–555, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Brabender, J. Park, R. Metzger et al., “Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer,” Annals of Surgery, vol. 235, no. 3, pp. 440–443, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Ristimaki, A. Sivula, J. Lundin et al., “Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer,” Cancer Research, vol. 62, no. 3, pp. 632–635, 2002. View at Google Scholar · View at Scopus
  44. O. Gallo, E. Masini, B. Bianchi, L. Bruschini, M. Paglierani, and A. Franchi, “Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma,” Human Pathology, vol. 33, no. 7, pp. 708–714, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Konno, M. Baba, T. Shoji, M. Ohta, S. Suzuki, and S. Nakamura, “Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer,” Clinical and Experimental Metastasis, vol. 19, no. 6, pp. 527–534, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Ferrandina, L. Lauriola, G. F. Zannoni et al., “Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications,” British Journal of Cancer, vol. 87, no. 10, pp. 1145–1152, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Li, G. S. Ren, H. Y. Li, X. Y. Wang, L. Chen, and J. Li, “A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer,” Clinical Oncology, vol. 21, no. 4, pp. 302–305, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Shen, M. D. Gammon, M. B. Terry, S. L. Teitelbaum, A. I. Neugut, and R. M. Santella, “Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk,” Breast Cancer Research, vol. 8, no. 6, article R71, 2006. View at Publisher · View at Google Scholar · View at Scopus